Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 81974129, 82171038, 82101101 | Other Grant/Funding Number | the National Natural Science Foundation of China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy
The study aims to analyze the impact of intravitreal and intracameral DEX in diabetic patients with NPDR who are undergoing phacoemulsification surgery. Specifically, the investigators will investigate its effects on postoperative macular central thickness, the development of DME, and the progression of DR.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| intravitreal DEX group | Experimental | Patients received an intravitreal injection of 0.5 mg DEX during phacoemulsification in the intravitreal DEX group |
|
| intracameral DEX group | Experimental | Patients received an intracameral injection of 0.5 mg DEX during phacoemulsification in the intracameral DEX group |
|
| the control group | No Intervention | Patients received no injection during phacoemulsification in the control group |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexamethasone sodium phosphate | Drug | In patients with stable DR and no significant macular edema, intravitreal anti-VEGF injections after phacoemulsification surgery can prevent the worsening of postoperative macular edema and potentially improve final visual outcomes while maintaining safety. Laser coagulation and intravitreal anti-VEGF injections are currently considered the standard treatments for PDR. However, the cost of anti-VEGF drugs often prevents many patients from receiving regular and timely injections. Intravitreal corticosteroids may be used as an alternative to anti-VEGF agents. |
| Measure | Description | Time Frame |
|---|---|---|
| measure the central point thickness (CPT) and central foveal thickness (CFT) | optical coherence tomography (OCT) was used to perform the retinal examination, macular cube scans (512 × 128) and measure the central point thickness (CPT) and central foveal thickness (CFT). The CPT measurement focused on a central circle with a diameter of 1mm, and the CFT was calculated as the average of three consecutive measurements | From enrollment to the end of treatment at 3 months |
Not provided
Not provided
Inclusion Criteria:
type 2 diabetic cataracts patients who were diagnosed with mild to moderate NPDR
Exclusion Criteria:
-
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Eye Institute, Affiliated Hospital of Nantong University | Nantong | Jiangsu | 226001 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008269 | Macular Edema |
| ID | Term |
|---|---|
| D008268 | Macular Degeneration |
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C004180 | dexamethasone 21-phosphate |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|